Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Helena is passionate about innovation and how one can turn ideas into concrete products and solutions. She is an expert in biotechnology and pharmaceutical backgrounds, dealing also with innovation and entrepreneurship, with a special focus on marine biotechnology and product development for pharmaceutical, personal care and cosmetics, nutraceutical and consumer goods markets. She has founded two start-ups, including BIOALVO, a top class biotech company developing natural and small molecule ingredients for various markets. She is part of major international and national decision and strategy making boards, including FP7 and H2020. Her range of action goes from pharma and biotech product development, regulatory and intellectual property management, clinical development, business strategy, leadership and innovation, resource management, entrepreneurship and education. Currently, she is Executive Director of BLUEBIO ALLIANCE, the Portuguese network for the marine bioresources sector. She is also a Professor at FCUL and a PI at BioISI, where she is responsible for the blue biotechnology unit of the M&B lab.
Alan has worked in Health Care and Medical Research, as Chairman and Chief Executive of large multinational companies and smaller technology start-ups. He teaches in Universities in UK, Europe, North America and Asia with Professorships in European and Chinese Universities. He has raised and managed a Venture Capital Fund, is a Business Angel Investor and Trustee of charities. He has been honoured with The Queen’s Award for Enterprise Promotion in the UK and with membership as Knight First Class of the Order of the White Rose of Finland for services to Education. His current work is focussed heavily on the commercialisation of research, technology start-ups and the development of UK-China Trade and Relationships including cross-continental investment. Alan promotes the vision of “A World Without Borders”. Alan’s work with Shanghai Government, Hong Kong Management Association and numbers of overseas business and academic organisations commissioning world class executive education programmes has prepared him well to be Director of Studies at Cambridge Innovation Academy.
Leader of the Medical Devices group at INL and CEO of RUBYnanomed. Her research is focused on the development of biomicrofluidic devices mainly devoted to Translational Medical Research in close collaboration with Hospitals. For that purpose, her work is devoted to the development of integrated biosensing systems and nanobioengineered diagnostics microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients, as well as the development of microfluidic organ-on-a-chip 3D models. Lorena is also very interested in translating her technology from the lab to the clinic, and she has been very active in her endeavours as entrepreneur, creating the spin-off company RUBYnanomed in the field of liquid biopsy. She obtained her Bachelor’s degree in Physics and her Masters in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanoscience and Nanotechnology at the University of Barcelona (UB) in 2007 and obtained her PhD in Nanosciences in optical and electrochemical biosensors at the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoctoral research at the University of South Australia (UniSA) from 2010 was devoted to the study of rare cells from biological samples using microfluidics.
Diana Prata has a Marie Curie fellowship grant and, as FCT-Investigator, is the Principal Investigator of the Biomedical Neuroscience Lab at Instituto de Biofísica e Engenharia Biomédica da Universidade de Lisboa, after 12 years at the Institute of Psychiatry, Psychology and Neuroscience of the King's College London where she is still a Visiting Lecturer. In 2017, she won the 3rd Marie Curie Actions Award for "Most Promising Scientist in Innovation and Entrepreneurship". Her lab is dedicated to the study of the biology of human behaviour, which aims to translate into the improvement of the etiological and therapeutic models of neuropsychiatric diseases; and she is the Chief Scientific Officer and co-founder of NeuroPsyAI, developing diagnostic solutions for neurodegenerative illnesses.
Ferron is the Founder & President of Grae Matta Group. A Group of Organisations whose mandate is to improve Mental Health in Higher Education and the Workplace by developing and influencing organisational policy. Grae Matta Foundation is one of those companies. Its a non-profit organisation that’s aimed to aid institutions, organisations and businesses develop unique mental health policies, standards and campaigns which are specifically applicable to their industry. This has never been done before as no National or International Standards exist in Mental Health. Having a standardised way of deploying services would save Billions if not Trillions of Pounds. In the UK stress accounts for 45% of lost working days in an average working year, and £105,000,000,000 to the economy. Mental health disorders are on the rise in every country in the world and could cost the global economy up to £12.5 trillion between 2010 and 2030. Ferron founded Grae Matta to create awareness and subsequently create change. Ferron is a Highly Specialised Forensic Psychologist. Member of the Institute of Directors (IoD) and British Chamber of Commerce, UK Representative for the G20 YEA (Young Entrepreneurs Alliance) and also member of the B20 Education & Employment Taskforce representing the United Kingdom.
Wolfgang is a passionate entrepreneur and executive coach from the heart of Austria. Representing the Swiss based M&A consultancy BridgeLink he is also an expert for growth financing. His projects lead him around the globe – currently with a strong focus on Europe. Petroleum Engineer by trade he is currently consulting for the European Commission and its Horizon 2020 SME program. Working with various industries, project sizes, cultures, business models and leadership types, Wolfgang's core drive is curiosity: exploring and making the best of new situations. He thrives by establishing a deep understanding of the various layers and aspects of his projects, striving to offer unique, tailor made organisations and strategies in line with company cultures and values. Consequently every coaching project follows three key phases: exploration, alignment, execution. During exploration the current status is – well – explored: mainly understanding project, people and planning. During alignment consistency, authenticity and plausibility are questioned and established. In the execution phase the key goal is to transform company‘s weaknesses into strengths. Wolfgang‘s current project portfolio includes Technology / Software, OEM / Commodities, Life Science / MedTech, innovative Energy solutions and new currencies. In his free time he loves travelling, cooking and exploring new social concepts.
Pete Andersen is CEO at a Swedish tech startup called Watersprint. We are a small company but with a really big vision - “To offer all people on this planet safe water in a sustainable way”. In short, Watersprint is using the foundations of the Nobel Prize in physics 2014 - generating UV light from the relatively new LED technology - in its patented products in order to optimize disinfection in running water. This new technology has major advantages over the traditional ones - no mercury or other chemicals are ever used, extremely energy efficient, robust and IoT-capable. The latter aspect is getting increasingly important with the emergence of smart homes. Watersprint has recently formed a couple of strategically important deals of cooperation, which we now started to deliver upon. Besides being wrapped up in disinfecting drinking water in various parts of the world, Pete just acquired a mini-hen farm in the middle of Malmö city. Last week, the first proud egg arrived!
Co-founder and CEO at Nano4 - Nanotechnology company applied to diagnostics, since 2016. President of P-BIO Portugal’s Biotech Industry Organization since 2015. During 12 years, from 2003 to 2015, gain multi-country corporate experience at Genzyme, including served as Country manager of Portugal. Leadership roles in merger and crisis situations. Successful exit as a retail entrepreneur. Pharmacy Degree from the University of Coimbra and MBA from AESE/IESE Business School.
Caleb is a serial entrepreneur, international speaker, award-winning and best-selling author of ‘Futureproof: How To Get Your Business Ready For Your Next Disruption.‘ He speaks on entrepreneurialism, marketing and leadership. Caleb works as an international consultant with RBS, Barclays, Canon, Visa, AMEX, PMI and many other multinationals. Founder and CEO of digital marketing agency, Storkey Media, Caleb supports and advises highly ambitious, fast growth and highly disruptive tech startups and entrepreneurial teams.
Exogenus Therapeutics is a drug development company using an exosome-based platform technology to develop an innovative pipeline of therapeutic products. Leveraging on the strong regenerative, anti-inflammatory and immunomodulatory properties of our proprietary vesicles, we are developing therapeutic tools for skin and autoimmune diseases. Our lead product Exo-Wound is an hydrogel containing exosomes secreted by Umbilical Cord Blood cells for the treatment of chronic wounds, and will reach clinical studies in 2020. Exogenus Therapeutic aims to became a company of reference in the area of exosome-based therapeutics worldwide, and among the few that will bring exosomes to the clinic in the coming years.
O Monarch foi um projecto Europeu, financiado pelo 7º Programa Quadro entre 2013 e 2016. Na concepção original, o Monarch teve como objetivos o estudo dos efeitos da presença de um robot social, capaz de actividades de entretenimento básico junto de um público infantil no contexto da ala Pediátrica do IPOLFG, Lisboa, e, simultaneamente, avaliar soluções técnicas e científicas para robots sociais em ambientes não-laboratoriais genéricos. O robot Gasparzinho, desenvolvido no âmbito do Monarch, é capaz de interacções sociais simples, baseadas em toque e em sons verbais e não-verbais, e de reconhecer pessoas que transportem consigo um identificador próprio. É ainda capaz de jogar jogos não-competitivos com as crianças.
Matera has developed a proprietary technology that allows the production of coatings with broad-spectrum antimicrobial properties (bacteria, fungi and virus) for materials and surfaces. The technology is based on the efficient and homogeneous conjugation of nanoparticles and biocidal agents that confers to the coatings a durable antimicrobial effect without leaching the bioactive compounds. Matera has been focusing on different markets, including building materials (e.g. plywood, aluminium and paints), textiles and biomedical materials.
BestHealth4U is bringing the new generation of medical-grade adhesives to market. It's main product, Bio2Skin, is a revolutionary new generation medical-grade adhesive with a wide range of uses in medical devices and wound dressings. The new adhesive material is an alternative to the current glues used in the application of devices and dressings to the skin, which usually provokes severe skin problems.